BRIEF-Relmada Gets FDA Support For Two Registrational Study Paths For NDV-01 In Non-Muscle Invasive Bladder Cancer

Reuters11-04

Nov 4 (Reuters) - Relmada Therapeutics Inc RLMD.O:

RELMADA ANNOUNCES FDA FEEDBACK SUPPORTING 2 SEPARATE ACCEPTABLE REGISTRATIONAL STUDY PATHS FOR NDV-01 IN NON-MUSCLE INVASIVE BLADDER CANCER
RELMADA THERAPEUTICS INC - FDA CONFIRMS NO ADDITIONAL NON-CLINICAL STUDIES REQUIRED FOR NDV-01
RELMADA THERAPEUTICS INC - NDV-01 SHOWS 92% RESPONSE RATE IN NMIBC WITH GOOD SAFETY
RELMADA THERAPEUTICS INC - SECURES FDA ALIGNMENT FOR PHASE 3 NDV-01 PROGRAM
RELMADA THERAPEUTICS INC: INITIATING PHASE 3 PROGRAMS IN FIRST HALF OF 2026

Source text: ID:nGNX3786vB

Further company coverage: RLMD.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2580739041?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-04 20:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2580739041","market":"us","top_or_hot":-1,"title":"BRIEF-Relmada Gets FDA Support For Two Registrational Study Paths For NDV-01 In Non-Muscle Invasive Bladder Cancer","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Relmada Gets FDA Support For Two Registrational Study Paths For NDV-01 In Non-Muscle Invasive Bladder Cancer</title></head><body><p><span>Nov 4 (Reuters)</span><span> - </span>Relmada <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc <span>RLMD.O</span>:</p><ul><li><p>RELMADA ANNOUNCES FDA <a href=\"https://laohu8.com/S/FDBK.UK\">FEEDBACK</a> SUPPORTING 2 SEPARATE ACCEPTABLE REGISTRATIONAL STUDY PATHS FOR NDV-01 IN NON-MUSCLE INVASIVE BLADDER CANCER</p></li><li><p>RELMADA THERAPEUTICS INC - FDA CONFIRMS NO ADDITIONAL NON-CLINICAL STUDIES REQUIRED FOR NDV-01</p></li><li><p>RELMADA THERAPEUTICS INC - NDV-01 SHOWS 92% RESPONSE RATE IN NMIBC WITH GOOD SAFETY</p></li><li><p>RELMADA THERAPEUTICS INC - SECURES FDA ALIGNMENT FOR PHASE 3 NDV-01 PROGRAM</p></li><li><p>RELMADA THERAPEUTICS INC: INITIATING PHASE 3 PROGRAMS IN FIRST HALF OF 2026</p></li></ul><p>Source text: <span>ID:nGNX3786vB</span></p><p>Further company coverage: <span>RLMD.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Relmada Gets FDA Support For Two Registrational Study Paths For NDV-01 In Non-Muscle Invasive Bladder Cancer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Relmada Gets FDA Support For Two Registrational Study Paths For NDV-01 In Non-Muscle Invasive Bladder Cancer\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-04 20:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Relmada Gets FDA Support For Two Registrational Study Paths For NDV-01 In Non-Muscle Invasive Bladder Cancer</title></head><body><p><span>Nov 4 (Reuters)</span><span> - </span>Relmada <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc <span>RLMD.O</span>:</p><ul><li><p>RELMADA ANNOUNCES FDA <a href=\"https://laohu8.com/S/FDBK.UK\">FEEDBACK</a> SUPPORTING 2 SEPARATE ACCEPTABLE REGISTRATIONAL STUDY PATHS FOR NDV-01 IN NON-MUSCLE INVASIVE BLADDER CANCER</p></li><li><p>RELMADA THERAPEUTICS INC - FDA CONFIRMS NO ADDITIONAL NON-CLINICAL STUDIES REQUIRED FOR NDV-01</p></li><li><p>RELMADA THERAPEUTICS INC - NDV-01 SHOWS 92% RESPONSE RATE IN NMIBC WITH GOOD SAFETY</p></li><li><p>RELMADA THERAPEUTICS INC - SECURES FDA ALIGNMENT FOR PHASE 3 NDV-01 PROGRAM</p></li><li><p>RELMADA THERAPEUTICS INC: INITIATING PHASE 3 PROGRAMS IN FIRST HALF OF 2026</p></li></ul><p>Source text: <span>ID:nGNX3786vB</span></p><p>Further company coverage: <span>RLMD.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nTUA8NSXQG:1","article_id":"2580739041","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2580739041","pubTimestamp":1762260390,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Relmada Gets FDA Support For Two Registrational Study Paths For NDV-01 In Non-Muscle Invasive Bladder CancerNov 4 (Reuters) - Relmada Therapeutics Inc RLMD.O:RELMADA ANNOUNCES FDA FEEDBACK SUPPO","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","RLMD":"Relmada Therapeutics, Inc."},"translate_title":"简介-Relmada获得FDA对NDV-01治疗非肌层浸润性膀胱癌的两条注册研究路径的支持","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RLMD":0.9},"content_text":"BRIEF-Relmada Gets FDA Support For Two Registrational Study Paths For NDV-01 In Non-Muscle Invasive Bladder CancerNov 4 (Reuters) - Relmada Therapeutics Inc RLMD.O:RELMADA ANNOUNCES FDA FEEDBACK SUPPORTING 2 SEPARATE ACCEPTABLE REGISTRATIONAL STUDY PATHS FOR NDV-01 IN NON-MUSCLE INVASIVE BLADDER CANCERRELMADA THERAPEUTICS INC - FDA CONFIRMS NO ADDITIONAL NON-CLINICAL STUDIES REQUIRED FOR NDV-01RELMADA THERAPEUTICS INC - NDV-01 SHOWS 92% RESPONSE RATE IN NMIBC WITH GOOD SAFETYRELMADA THERAPEUTICS INC - SECURES FDA ALIGNMENT FOR PHASE 3 NDV-01 PROGRAMRELMADA THERAPEUTICS INC: INITIATING PHASE 3 PROGRAMS IN FIRST HALF OF 2026Source text: ID:nGNX3786vBFurther company coverage: RLMD.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2580739041","isCrawlerRequest":true}